Obermatt
See Similar Stocks →

Formosa Laboratories

TAI:4746 · TW0004746003
PharmaceuticalsSmall

360

63
Medium confidence — indicative
Profit price1
Owner Earnings Yield62
Dividend Yield1
Price/Sales51
EV / Gross Profit49
Price/Book74
Return on Capital83
Cash Return on Capital63
Return on Equity67
EBIT Margin92
Gross Profitability38
Cash Conversion100
Accruals41
Owner Earnings Margin61
Sales growth22
Profit Growth15
Long-Term EPS Growth43
Reinvestment90
Price momentum36
Debt load38
Refinancing57
Debt Payback7
Liquidity77
Analyst ratings62
Expectations trend50
Market mood34
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Formosa Laboratories clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryTaiwan
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeTWSE
Founded1985
Employees102
Websiteformosalab.com
ISINTW0004746003
Last UpdateApr 2, 2026
Index & Theme
Pain ManagementCentral Nervous SystemRespiratoryInflammationOncologyBiotechnologyManufacturingPharmaceutical

Description

Analysis

Quality compounder

Formosa Laboratories, Inc. earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.

On valuation, the picture is expensive. The owner-earnings multiple stands at 379.9×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is adequate. The company scores 10/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
25
2023202420252026

All-time high

92

Jan 2024

All-time low

25

Jun 2026

Average rank

64

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
51
50
43
56
Price/Earnings
40
93
81
97
Price/Book
74
57
51
84
Dividend Yield
1
98
91
83
Value (overall)
42
84
76
93

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Formosa Laboratories with its peers
Lotus Pharmaceutical
TAI:1795
19
CountryTaiwan
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Reyon Pharmaceutical
KSC:102460
16
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Belite Bio
NAQ:BLTE
49
CountryTaiwan
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Ilsung IS
KSC:003120
59
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Ildong Holdings
KSC:000230
83
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Yungjin Pharm
KSC:003520
34
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →